STOCK TITAN

STANDARD BIOTOOLS (LAB) SEC Filings, Aug-Oct 2026

LAB NASDAQ

Standard BioTools Inc. filings document the regulatory record for a life-science research tools company centered on mass cytometry, microfluidics, genomics, single-cell proteomics and spatial proteomics. Current reports cover operating results, revenue outlook disclosures, restructuring and cost-savings actions, capital-structure changes, material agreements and risk factors tied to its research-use instrument, consumable and service portfolio.

Proxy materials describe board elections, executive compensation votes, auditor ratification, equity incentive plan approvals and employee stock purchase plan amendments. Form 8-K filings also record material events such as the completed SomaLogic sale, related financial disclosures, shareholder voting matters and Nasdaq continued-listing compliance notices.

Rhea-AI Summary

Standard BioTools Inc. (LAB) is registering up to 364,223,328 shares of common stock in a primary prospectus tied to its proposed all-stock merger with Treeline Biosciences. Separate resale prospectus pages cover shares Treeline holders receive and may resell; Standard BioTools will receive no proceeds from those resales. Subject to required stockholder approvals and other closing conditions, Treeline would become a wholly owned subsidiary and Standard BioTools would be renamed Treeline Biosciences, Inc.

Based on capitalization as of October 6, 2026, the estimated exchange ratio is 11.1202 to 11.7157 Standard BioTools shares per Treeline share before a proposed 1-for-20 to 1-for-40 reverse split, with the final split ratio to be mutually agreed. The exchange ratio may change with actual closing capitalization and Parent Net Cash. Former Treeline holders are expected to own approximately 84% of the combined company and former Standard BioTools holders approximately 16%, subject to adjustments. Standard BioTools expects to distribute one contingent value right per share held on the last business day before the Effective Time; potential payments would be based on specified proceeds during the five-year term, with a maximum of 76,000,000 shares issuable. The mass cytometry sale to Element requires stockholder approval and completion of the merger; a separate agreement provides for ARCHIMED to acquire the microfluidics business.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
registration
-
Rhea-AI Summary

Standard BioTools Inc. is registering up to 364,223,328 common shares for issuance in its proposed all-stock merger with Treeline Biosciences.

Merger Sub will merge into Treeline, which will survive as Standard BioTools’ wholly owned subsidiary, and Standard BioTools is to be renamed Treeline Biosciences. The merger requires Standard BioTools stockholder approval of the share issuance and charter amendment. Former Treeline holders are expected to own approximately 84% of the combined company on a fully diluted basis, versus approximately 16% for former Standard BioTools holders; ownership may adjust based on Parent Net Cash at closing. Based on capitalization as of October 6, 2026, the estimated exchange ratio is approximately 11.1202 to 11.7157 Standard BioTools shares per Treeline share before the proposed 1-for-20 to 1-for-40 reverse stock split, and may change by closing.

Standard BioTools expects one contingent value right per share held on the last business day before the Effective Time. Over five years, any CVR payments would be based on specified net proceeds; up to 76,000,000 combined-company shares may be issued, but payment is not assured. Certain Treeline holders may resell merger shares, from which Standard BioTools receives no proceeds. Element is to acquire the mass cytometry business subject to merger-related conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
registration
-
Rhea-AI Summary

Standard BioTools Inc. announced on October 5, 2026, that it had entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm focused exclusively on healthcare industries. The transaction is expected to close in approximately 30 days, subject to customary closing conditions. Standard BioTools identified possible delay or non-completion, closing conditions that may not be satisfied or waived, events that could permit termination—including circumstances that would require it to pay a termination fee or other expenses—and competing offers or acquisition proposals as risks to completion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
merger
Rhea-AI Summary

Standard BioTools Inc. (LAB) entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm focused exclusively on healthcare industries. The transaction is expected to close in approximately 30 days, subject to customary closing conditions.

Until closing, Microfluidics will continue to operate as part of Standard BioTools. The company said the sale may not be completed in a timely manner or at all, and that closing conditions may not be satisfied or waived.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
current report
-
Rhea-AI Summary

Standard BioTools Inc. agreed to sell its mass cytometry business to Element Biosystems, LLC, a wholly owned subsidiary of GMT Venture Partners, for an aggregate purchase price of $5.5 million in cash, on a cash-free and debt-free basis and subject to customary adjustments. The sale remains subject to Standard BioTools stockholder approval, consummation of its pending merger with Treeline Biosciences, and other customary closing conditions.

The agreement follows termination of Standard BioTools’ prior sale agreement with Multiplex Bio after the board determined it had received a “Business Superior Proposal.” Standard BioTools agreed to pay Multiplex a $1.5 million termination fee; GMT Venture agreed to pay $1.0 million to Multiplex on Standard BioTools’ behalf as partial satisfaction. At closing, the parties contemplate a transition services agreement under which Standard BioTools will provide specified services to Element. Under specified termination circumstances, Standard BioTools will be required to pay Element a $1.0 million fee. The company must also reimburse reasonable out-of-pocket fees up to $125,000 if the sale is not consummated prior to December 31, 2026, and up to an additional $125,000 if it is not consummated prior to March 31, 2027; reimbursements are credited against any termination fee.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
merger
-
Rhea-AI Summary

Standard BioTools (LAB) entered into an agreement under which Element Biosystems, LLC, an acquisition vehicle formed by GMT Venture, will acquire its mass cytometry business for $5.5 million in cash, subject to customary adjustments. The sale requires stockholder approval, completion of the Treeline merger and other customary conditions, and is expected to close by the end of 2026, substantially concurrently with the merger.

Standard BioTools and Multiplex Bio mutually terminated their earlier agreement, and Standard BioTools agreed to pay a $1.5 million termination fee. GMT Venture agreed to pay Multiplex Bio $1.0 million directly or indirectly on Standard BioTools’ behalf toward that fee. Standard BioTools said the Element terms would increase by approximately $15 million the net cash used to calculate the Treeline merger’s final exchange ratio versus Multiplex, after related fees; the comparison also reflects the former agreement’s required $10 million working-capital loan.

The Element agreement has no financing condition. Either party may terminate if the sale is not completed on or before June 30, 2027, subject to up to two automatic three-month extensions in specified circumstances. In specified termination circumstances, Standard BioTools may owe Element a $1.0 million fee and may have to refund GMT Venture’s contribution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
current report
Rhea-AI Summary

STANDARD BIOTOOLS INC. (LAB) is seeking stockholder approval for an all‑stock merger with Treeline Biosciences, Inc., registering up to 2,101,718,733 shares of its common stock for issuance in the Merger and for resale by Treeline stockholders. The combined company will be renamed Treeline Biosciences Holdings, Inc. and is expected to trade on Nasdaq under the symbol “TRLN.”

The Merger exchange ratio is based on an assumed $2.5 billion equity value for Treeline and $460 million for Standard BioTools, adjusted for Parent Net Cash, implying pro forma ownership of about 84% for former Treeline holders and 16% for current Standard BioTools holders on a fully diluted basis. Standard BioTools will also effect a Charter Amendment to change its name and implement a reverse stock split within a specified ratio range.

Standard BioTools plans to divest its mass cytometry business to Multiplex Bio Inc. under a Share and Asset Purchase Agreement, and use commercially reasonable efforts to monetize its remaining Legacy Businesses. Existing stockholders are expected to receive one contingent value right (CVR) per share, with up to 76,000,000 combined‑company shares potentially issuable over five years from Legacy Businesses monetizations and other specified proceeds. The transaction is structured as a reverse recapitalization with Treeline as the accounting acquirer, so Treeline’s historical financials will become those of the combined company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.13%
Tags
registration
-
Rhea-AI Summary

STANDARD BIOTOOLS INC. (LAB) reported that executive Sean Mackay, SVP & Chief Business Officer, had 25,729 shares of common stock withheld on August 20, 2026 to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this tax-withholding disposition, he holds 1,480,823 shares of common stock directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
-
Rhea-AI Summary

STANDARD BIOTOOLS INC. (LAB) reported that Chief Financial Officer Hanjoon Alex Kim had 28,195 shares of common stock withheld on August 20, 2026 to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. This was a code F transaction, meaning shares were delivered or withheld for tax payment rather than sold in the open market. After this withholding, Kim directly held 2,534,859 shares of STANDARD BIOTOOLS common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
Rhea-AI Summary

STANDARD BIOTOOLS INC. (LAB) reported that President & CEO Michael Egholm had 97,627 shares of common stock withheld on August 20, 2026 to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this tax-withholding disposition, he directly holds 6,137,704 shares of common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider

FAQ

How many STANDARD BIOTOOLS (LAB) SEC filings are available on StockTitan?

StockTitan tracks 108 SEC filings for STANDARD BIOTOOLS (LAB), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for STANDARD BIOTOOLS (LAB)?

The most recent SEC filing for STANDARD BIOTOOLS (LAB) was filed on November 16, 2026.